ImmuneSensor Therapeutics is a clinical-stage biotechnology company focused on developing novel medicines that target the cGAS-STING pathway to modulate the innate immune system. Based on groundbreaking discoveries from the research of the 2019 Breakthrough Prize awardee, Dr. Zhijian “James” Chen, we are pioneering a differentiated approach to both STING activators to boost anticancer immunity and cGAS inhibitors to suppress autoimmunity when the immune system is overactive.
Discovery of cGAS – the DNA-sensing enzyme – and its secondary messenger cGAMP by Dr Chen’s research group in 2012, has revolutionized research into the role of the cGAS-STING pathway in innate immunity. The broad applicability of the pathway in many diseases is now widely recognized as it plays a critical role in activating an innate immune defense against cytosolic DNA from pathogens, damaged tumor cells or other cellular stress.
At ImmuneSensor, we are leveraging this important pathway to develop STING agonists including immune stimulatory ADC, for the treatment of cancers and cGAS antagonists for the treatment of a range of autoimmune diseases.
We are advancing differentiated potentially first- and
best-in-class candidates with the goal of improving the lives of
patients with serious and rare disease.